Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Current Assets (2023 - 2025)

Historic Current Assets for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $296.6 million.

  • Zenas BioPharma's Current Assets fell 2466.77% to $296.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.6 million, marking a year-over-year decrease of 2466.77%. This contributed to the annual value of $355.9 million for FY2024, which is 49514.92% up from last year.
  • As of Q3 2025, Zenas BioPharma's Current Assets stood at $296.6 million, which was down 2466.77% from $278.6 million recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Current Assets peaked at $393.8 million during Q3 2024, and registered a low of $59.8 million during Q4 2023.
  • Its 3-year average for Current Assets is $283.8 million, with a median of $307.2 million in 2025.
  • In the last 5 years, Zenas BioPharma's Current Assets skyrocketed by 49514.92% in 2024 and then plummeted by 2466.77% in 2025.
  • Zenas BioPharma's Current Assets (Quarter) stood at $59.8 million in 2023, then surged by 495.15% to $355.9 million in 2024, then fell by 16.66% to $296.6 million in 2025.
  • Its last three reported values are $296.6 million in Q3 2025, $278.6 million for Q2 2025, and $317.8 million during Q1 2025.